$ALVO

AstraZeneca (AZN) received FDA approval for Ultomiris in IgA nephropathy, with a 43.4% reduction in proteinuria. Merck (MRK) got EU approval for KEYTRUDA plus Padcev in bladder cancer, showing a 35% reduction in death risk. Alvotech (ALVO) approved a new manufacturing process for SIMLANDI. Cytokinetics (CYTK) won Health Canada approval for MYQORZO in obstructive HCM. Viatris (VTRS) approved RYZUMVI for presbyopia. Enlivex (ENLV) and EyePoint (EYPT) announced significant workforce reductions.

U.S. stock index futures were mixed on Tuesday, with tech stocks under pressure. Halliburton (HAL) rose 3.4% after beating earnings expectations. Rapport Therapeutics (RPTX) surged 31.1% on positive Phase 2 trial results. NuScale Power (SMR) fell 6.5% after a downgrade. Akamai (AKAM) gained 2.2% following an upgrade. General Motors (GM) dropped 6.3% after disappointing investors with its outlook. Alvotech (ALVO) rose 7% after FDA approval. 3M (MMM) gained over 1% on Amazon partnership expansion.

Alvotech (ALVO) received FDA approval for a new manufacturing process that more than doubles SIMLANDI output per batch. This follows recent capacity approvals, focusing on scale and cost efficiency in biosimilars. The company aims to show market share gains and margin improvements.

Alvotech submitted its first aflibercept 8 mg biosimilar for review to the European Medicines Agency. The company aims to bring a biosimilar version of the drug to market, which could impact the ophthalmology sector and competitors in the biosimilar space.

Alvotech (ALVO) submitted AVT29, a biosimilar to Eylea 8 mg, to the EMA. The company claims this is the first global regulatory submission for an Eylea 8 mg biosimilar, expanding its aflibercept strategy beyond the approved 2mg version.

Roche, Novartis, Pfizer, and Eli Lilly received FDA approvals for their drugs. Lupin and Lipocine also gained regulatory nods. Caribou Biosciences plans to cut workforce and discontinue programs. Several biopharma companies announced deals and partnerships. Stock prices for mentioned companies varied.

Alvotech (ALVO) and LOTTE Biologics announced a long-term manufacturing partnership. LOTTE will produce biosimilar drugs at its New York facility, expanding Alvotech's global supply. The deal aims to meet growing demand and support Alvotech's portfolio expansion. Both companies highlighted the strategic benefits and regulatory readiness of the Syracuse site.

Alvotech (ALVO) received FDA approval to double production capacity for its Humira biosimilar, SIMLANDI, addressing prior inspection issues and potentially increasing U.S. supply. The company faces high debt and negative equity but analysts project significant revenue growth by 2029. The approval could impact Alvotech's earnings and operational efficiency, with varying analyst expectations on future performance.

Alvotech's shares rose 13% after the FDA approved additional U.S. manufacturing capacity for its Humira biosimilar, Simlandi. The approval doubles production capacity and suggests past plant issues may be resolved. FDA decisions on other biosimilars are expected in Q4 2026. According to the CEO, the approval effectively doubles the drug substance manufacturing capacity for U.S. supply.

Alvotech (ALVO) stock rose 8.1% in pre-market trading after FDA approved a supplement to its Biologics License Application for AVT02, doubling U.S. manufacturing capacity. The approval resolves inspection issues and may accelerate reviews of other biosimilar applications. Analysts had recently upgraded the stock to Overweight with an $8 price target.